Ключевые слова:
tizimli qizil bo‘richa, lupus nefriti, gidroksixloroxin, glyukokortikosteroidlar, belimumab, anifrolumab, voklosporin, obinutuzumab, CAR-T terapiya, treat-to-target.Библиографические ссылки
1. Fanouriakis A, Kostopoulou M, Andersen J, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis. 2024;83(1):15–29.
2. Fanouriakis A, Kostopoulou M, Anders HJ, et al. EULAR recommendations for the management of systemic lupus erythematosus with kidney involvement: 2025 update. Ann Rheum Dis. 2025 (Oct issue).
3. Sammaritano LR, Askanase A, Bermas BL, et al. 2024 American College of Rheumatology (ACR) Guideline for the Screening, Treatment, and Management of Lupus Nephritis. Arthritis Rheumatol. 2025.
4. Kidney Disease: Improving Global Outcomes (KDIGO) Work Group. KDIGO 2024 Clinical Practice Guideline for the Management of Lupus Nephritis. Kidney Int. 2024.
5. Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism/ American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis. 2019;78(9):1151–1159.
6. van Vollenhoven RF, Mosca M, Bertsias G, et al. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis. 2014;73(6):958–967.
7. van Vollenhoven RF, Bertsias G, Doria A, et al. 2021 DORIS definition of remission in SLE: final recommendations from an international task force. Lupus Sci Med. 2021;8(1):e000538.
8. Franklyn K, Lau CS, Navarra SV, et al. Definition and initial validation of a Lupus Low Disease Activity State (LLDAS). Ann Rheum Dis. 2016;75 (9):1615–1621.
9. Tian J, Zhang D, Yao X, Huang Y, Lu Q. Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study. Ann Rheum Dis. 2023;82(3):351–356.
10. Barber MRW, Drenkard C, Falasinnu T, et al. Global epidemiology of systemic lupus erythematosus. Nat Rev Rheumatol. 2021;17(9):515–532.
11. Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677–2686.
12. Ruiz-Irastorza G, Bertsias G. Treating systemic lupus erythematosus in the 21st century: new drugs and new perspectives on old drugs. Rheumatology (Oxford). 2020;59(Suppl 5):v69–v81.
13. Melles RB, Jorge AM, Marmor MF, et al. Hydroxychloroquine dose and risk for incident retinopathy: a cohort study. Ann Intern Med. 2023; 176(3):290–300.
14. Marmor MF, Kellner U, Lai TY, Melles RB, Mieler WF. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision). Ophthalmology. 2016;123(6):1386–1394.
15. Houssiau FA, Vasconcelos C, D'Cruz D, et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial. Arthritis Rheum. 2002; 46(8):2121–2131.
16. Navarra SV, Guzmán RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus (BLISS-52): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9767):721–731.
17. Furie R, Rovin BH, Houssiau F, et al. Two-year, randomized, controlled trial of belimumab in lupus nephritis (BLISS-LN). N Engl J Med. 2020; 383(12):1117–1128.
18. Furie R, Khamashta M, Merrill JT, et al. Anifrolumab, an anti-interferon-α receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus (MUSE). Arthritis Rheumatol. 2017; 69(2):376–386.
19. Morand EF, Furie R, Tanaka Y, et al. Trial of anifrolumab in active systemic lupus erythematosus (TULIP-2). N Engl J Med. 2020;382(3):211–221.
20. Rovin BH, Teng YKO, Ginzler EM, et al. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2021;397(10289):2070–2080.
21. Saxena A, Ginzler EM, Gibson K, et al. Safety and efficacy of long-term voclosporin treatment for lupus nephritis in the phase 3 AURORA 2 clinical trial. Arthritis Rheumatol. 2024;76(1):59–67.
22. Furie RA, Aroca G, Alvarez A, et al. B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial (NOBILITY). Ann Rheum Dis. 2022;81(1):100–107.
23. Furie RA, Rovin BH, Garg JP, et al. Efficacy and safety of obinutuzumab in active lupus nephritis (REGENCY). N Engl J Med. 2025.
24. Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis (LUNAR). Arthritis Rheum. 2012;64(4):1215–1226.
25. Mackensen A, Müller F, Mougiakakos D, et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat Med. 2022;28(10): 2124–2132.
26. Müller F, Taubmann J, Bucci L, et al. CD19 CAR T-cell therapy in autoimmune disease — a case series with follow-up. N Engl J Med. 2024;390 (8):687–700.
27. Matarneh A, Matarneh B, Salameh O, et al. Chimeric antigen receptor T cell therapy in systemic lupus erythematosus: mechanisms, clinical advances, and future directions. Clin Rev Allergy Immunol. 2025.
28. Andreoli L, Bertsias GK, Agmon-Levin N, et al. EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with SLE and/or antiphospholipid syndrome. Ann Rheum Dis. 2017;76(3):476–485.
29. Tektonidou MG, Andreoli L, Limper M, et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis. 2019;78(10):1296–1304.
30. Furer V, Rondaan C, Heijstek MW, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020;79 (1):39–52.
31. Aringer M, Costenbader K et al. 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheumatol. 2019 Sep;71(9):1400-1412. doi: 10.1002/art.40930. Epub 2019 Aug 6. PMID: 31385462; PMCID: PMC6827566.
32. McKeon KP, Jiang SH. Treatment of systemic lupus erythematosus. Aust Prescr 2020; 43: 85–90.
33. Liossis SN and Staveri C (2021) What's New in the Treatment of Systemic Lupus Erythematosus. Front. Med. 8:655100.
34. Flouda S, Boumpas D. Systemic lupus erythematosus: management strategies. Rare Dis Orphan Drugs J. 2025; 4:18.
35. Asqarov N.L. Analysis of the clinical progression characteristics of the disease in patients with systemic lupus erythematosus // Ideal Journal of Multidisciplinary Research Volume 01, – Issue 02, – February, 2026 – pp– 71–79 (14.00.00; (12) Index Copernicus, (14) ResearchBib).
36. Asqarov N.L., Nabiyeva D.A., Eraliyev U.E. Demographic and medico-social indicators of systemic lupus erythematosus in different regions // International multi-disciplinary journal for research & development eISSN 2394-6334 Impact factor: 7,854 Volume 12, – issue 12 – (2025) – pp – 1214 –1219 (14.00.00; (14) ResearchBib, (40) ResearchGate).
37. Asqarov N.L., Nabiyeva D.A., Eraliyev U.E., Tolipov U.U., Khikmatullayeva R.R. Interaction between genetic predisposition, environmental factors, and immune response in systemic lupus erythematosus (literature review) // Central Asian Journal of Medicine, – № 3, – 2026. – Vol. 3, – B – 157 – 164 (14.00.00; OAK 30.06.2020 283/7.1-son qarori).